Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer

Global cancer statistics, 2012

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,858 · see citing works

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · see citing works

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · see citing works

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895 · see citing works

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · see citing works

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848 · see citing works

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works

Whole genomes redefine the mutational landscape of pancreatic cancer

Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · see citing works

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works

Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer

Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J. M., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,418 · see citing works

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · see citing works

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · see citing works

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115 · see citing works

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

Cutsem, E. V., de Velde, H. J. V., Karásek, P., Oettle, H., Vervenne, W. L., Szawlowski, A. W., Schöffski, P., Post, S., Verslype, C., Neumann, H.-J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 784 · see citing works

Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways

Wu, J., Jiao, Y., Molin, M. D., Maitra, A., de Wilde, R. F., Wood, L. D., Eshleman, J. R., Goggins, M., Wolfgang, C. L., Canto, M. I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118046108 · Cited by 640 · see citing works

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Ueno, H., Ioka, T., Ikeda, M., Ohkawa, S., Yanagimoto, H., Boku, N., Fukutomi, A., Sugimori, K., Baba, H., Yamao, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3680 · Cited by 629 · see citing works

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

Ueno, H., Kosuge, T., Matsuyama, Y., Yamamoto, J., Nakao, A., Egawa, S., Doi, R., Monden, M., Hatori, T., Tanaka, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605256 · Cited by 438 · see citing works

<i>SMAD4</i> Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer

Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Eshleman, J. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0227 · Cited by 371 · see citing works

Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors

Yachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., Morgan, R. A., Saunders, T., Laheru, D. A., Herman, J. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1215 · Cited by 280 · see citing works

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

O'Brien, C. L., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H. M., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 256 · see citing works

Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

Chantrill, L. A., Nagrial, A. M., Watson, C., Johns, A. L., Martyn-Smith, M., Simpson, S. H., Mead, S., Jones, M. D., Samra, J. S., Gill, A. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0426 · Cited by 238 · see citing works

Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing

Iacobuzio–Donahue, C. A., Velculescu, V. E., Wolfgang, C. L., & Hruban, R. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0315 · Cited by 149 · see citing works

Prognostic Factors in Patients with Metastatic Pancreatic Adenocarcinoma Receiving Systemic Chemotherapy

Ueno, H., Okada, S., Okusaka, T., & Ikeda, M. (2000) · Oncology · doi:10.1159/000012186 · Cited by 99 · see citing works

Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas

Hidalgo, M. M., & Hoff, D. D. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1327 · Cited by 79 · see citing works

Deep Sequencing of Cancer-Related Genes Revealed GNAS Mutations to Be Associated with Intraductal Papillary Mucinous Neoplasms and Its Main Pancreatic Duct Dilation

Takano, S., Fukasawa, M., Maekawa, S., Kadokura, M., Miura, M., Shindo, H., Takahashi, E., Sato, T., & Enomoto, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098718 · Cited by 64 · see citing works

Prognostic Factors and Prognostic Index for Chemonaïve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer

Maréchal, R., Demols, A., Gay, F., de Maertelaere, V., Arvanitaki, M., Hendlisz, A., & Laethem, J. V. (2007) · Oncology · doi:10.1159/000120627 · Cited by 58 · see citing works

c-Kit Point mutation in patients with myeloproliferative disorders

Kimura, A., Nakata, Y., Katoh, O., & Hyodo, H. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709114167 · Cited by 46 · see citing works

Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma

Morizane, C., Okusaka, T., Morita, S., Tanaka, K., Ueno, H., Kondo, S., Ikeda, M., Nakachi, K., & Mitsunaga, S. (2011) · Pancreas · doi:10.1097/mpa.0b013e3182021376 · Cited by 40 · see citing works

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

Cicenas, J., Kvederavičiūtė, K., Meskinyte, I., Meškinytė-Kaušilienė, E., Skeberdytė, A., & Cicenas, J. (2017) · Cancers · doi:10.3390/cancers9050042 · Cited by 273 · see citing works

Cell-free DNA analysis in current cancer clinical trials: a review

Cisneros-Villanueva, M., Pérez, L. H., Ríos-Romero, M., Cedro‐Tanda, A., Ruiz-Villavicencio, C. A., Page, K., Hastings, R. K., Fernández-García, D., Allsopp, R. C., Fonseca-Montaño, M. A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01696-0 · Cited by 203 · see citing works

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110 · see citing works

Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients

Guo, S., Shi, X., Shen, J., Gao, S., Wang, H., Shen, S., Pan, Y., Li, B., Xu, X., Shao, Z., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0704-2 · Cited by 93 · see citing works

Comparison of endoscopic ultrasound-guided fine-needle biopsy versus fine-needle aspiration for genomic profiling and DNA yield in pancreatic cancer: a randomized crossover trial

Kandel, P., Nassar, A., Gómez, V., Raimondo, M., Woodward, T. A., Crook, J. E., Fares, N. S., & Wallace, M. B. (2020) · Endoscopy · doi:10.1055/a-1223-2171 · Cited by 93 · see citing works

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

Glassman, D. C., Palmaira, R. L. D., Covington, C. M., Desai, A. M., Ku, G. Y., Li, J., Harding, J. J., Varghese, A. M., O'Reilly, E. M., & Yu, K. H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4605-1 · Cited by 89 · see citing works

An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression

Khan, A. A., Liu, X., Yan, X., Tahir, M., Ali, S., & Huang, H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09952-0 · Cited by 78 · see citing works

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma

McIntyre, C. A., Lawrence, S., Richards, A. L., Chou, J. F., Wong, W., Capanu, M., Berger, M. F., Donoghue, M. T. A., Yu, K. H., Varghese, A. M., et al. (2020) · Cancer · doi:10.1002/cncr.33038 · Cited by 75 · see citing works

Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma

Kuwabara, S., Tsuchikawa, T., Nakamura, T., Hatanaka, Y., Hatanaka, K. C., Sasaki, K., Ono, M., Umemoto, K., Suzuki, T., Sato, O., et al. (2019) · Cancer Science · doi:10.1111/cas.14023 · Cited by 62 · see citing works

Pancreatic Cancer Biomarkers: Oncogenic Mutations, Tissue and Liquid Biopsies, and Radiomics—A Review

Amaral, M. J., Oliveira, R. C., Donato, P., & Tralhão, J. G. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07904-6 · Cited by 49 · see citing works

Next-Generation Sequencing in Pancreatic Cancer

Shen, G.-Q., Aleassa, E. M., Walsh, R. M., & Morris‐Stiff, G. J. (2019) · Pancreas · doi:10.1097/mpa.0000000000001324 · Cited by 45 · see citing works

Progress on diagnostic and prognostic markers of pancreatic cancer

YANG, H., Li, W., Ren, L., Yang, Y., Zhang, Y., Ge, B., Li, S., Zheng, X., Liu, J., Zhang, S., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028905 · Cited by 42 · see citing works

Genomic testing for pancreatic cancer in clinical practice as real-world evidence

Hayashi, H., Tanishima, S., Fujii, K., Mori, R., Okamura, Y., Yanagita, E., Matsuoka, R., Amano, T., Kinoshita, I., Komatsu, Y., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2018.07.006 · Cited by 39 · see citing works

Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress

Barcellini, A., Peloso, A., Pugliese, L., Vitolo, V., & Cobianchi, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s220971 · Cited by 36 · see citing works

Recent advances in precision medicine for pancreatic ductal adenocarcinoma

Hayashi, H., Higashi, T., Miyata, T., Yamashita, Y., & Baba, H. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12436 · Cited by 34 · see citing works

Roles of Smads Family and Alternative Splicing Variants of Smad4 in Different Cancers

Ullah, I., Sun, W., Tang, L., & Feng, J. (2018) · Journal of Cancer · doi:10.7150/jca.20906 · Cited by 36 · see citing works

An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms

Yao, H.-J., Song, W., Cao, R., Ye, C., Zhang, L., Chen, H., Wang, J., Shi, Y., Li, R. P., Li, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33037-x · Cited by 33 · see citing works

Combination of KRAS and SMAD4 mutations in formalin‐fixed paraffin‐embedded tissues as a biomarker for pancreatic cancer

Yokose, T., Kitago, M., Matsuda, S., Sasaki, Y., Masugi, Y., Nakamura, Y., Shinoda, M., Yagi, H., Abe, Y., Oshima, G., et al. (2020) · Cancer Science · doi:10.1111/cas.14425 · Cited by 28 · see citing works

Clinical Effect of Driver Mutations of <i>KRAS, CDKN2A/P16, TP53</i> , and <i>SMAD4</i> in Pancreatic Cancer: A Meta-Analysis

Gu, Y., Ji, Y., Jiang, H., & Qiu, G. (2020) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2020.0078 · Cited by 28 · see citing works

Characterization of pancreatic cancer with ultra-low tumor mutational burden

Imamura, T., Ashida, R., Ohshima, K., Uesaka, K., Sugiura, T., Ohgi, K., Yamada, M., Otsuka, S., Hatakeyama, K., Nagashima, T., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31579-8 · Cited by 27 · see citing works

Identification of genomic alterations and associated transcriptomic profiling reveal the prognostic significance of MMP14 and PKM2 in patients with pancreatic cancer

Wang, H., Wang, X., Xu, L., Lin, Y., Zhang, J., & Cao, H. (2020) · Aging · doi:10.18632/aging.103958 · Cited by 26 · see citing works

Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment

Asano, T., Hirano, S., Nakamura, T., Okamura, K., Tsuchikawa, T., Noji, T., Nakanishi, Y., Tanaka, K., & Shichinohe, T. (2018) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.565 · Cited by 25 · see citing works

Evaluation and diagnostic value of next‐generation sequencing analysis of residual liquid‐based cytology specimens of pancreatic masses

Sekita‐Hatakeyama, Y., Fujii, T., Nishikawa, T., Mitoro, A., Sawai, M., Itami, H., Morita, K., Uchiyama, T., Takeda, M., Sho, M., et al. (2021) · Cancer Cytopathology · doi:10.1002/cncy.22525 · Cited by 25 · see citing works

Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma

Matsumura, K., Hayashi, H., Uemura, N., Ogata, Y., Liu, Z., Sato, H., Shiraishi, Y., Kuroki, H., Kitamura, F., Kaida, T., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101533 · Cited by 25 · see citing works

Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment

Lu, J., Roy, B., Anderson, M. A., Leggett, C. L., Levy, M. J., Pogue, B. W., Hasan, T. G., & Wang, K. K. (2019) · Journal of Biomedical Optics · doi:10.1117/1.jbo.24.11.118001 · Cited by 25 · see citing works

SMAD4 Y353C promotes the progression of PDAC

Wang, Z., Li, Y., Zhan, S., Zhang, L., Zhang, S., Tang, Q., Li, M., Tan, Z., Liu, S., & Xing, X. (2019) · BMC Cancer · doi:10.1186/s12885-019-6251-7 · Cited by 25 · see citing works

Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?

Wu, C. L., Yang, P., Liu, B., & Tang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232464 · Cited by 23 · see citing works

Identification of key genes and pathways between type�I and type�II endometrial cancer using bioinformatics analysis

Zhang, K., Li, H., Yan, Y., Zang, Y., Li, K., Wang, Y., & Xue, F. (2019) · Oncology Letters · doi:10.3892/ol.2019.10550 · Cited by 23 · see citing works

Development of a 12-biomarkers-based prognostic model for pancreatic cancer using multi-omics integrated analysis

Jia, Y., Shen, M., Zhou, Y., & Liu, H. (2020) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5225 · Cited by 23 · see citing works

Post‐operative mortality and recurrence patterns in pancreatic cancer according to <i>KRAS</i> mutation and <scp>CDKN2A</scp> , p53, and <scp>SMAD4</scp> expression

Masugi, Y., Takamatsu, M., Tanaka, M., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2023) · The Journal of Pathology: Clinical Research · doi:10.1002/cjp2.323 · Cited by 23 · see citing works

KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer

Suzuki, T., Masugi, Y., Inoue, Y., Hamada, T., Tanaka, M. H., Takamatsu, M., Arita, J., Kato, T., Kawaguchi, Y., Kunita, A., et al. (2022) · Cancer Science · doi:10.1111/cas.15398 · Cited by 21 · see citing works

Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome

Shoucair, S., Habib, J. R., Pu, N., Kinny‐Köster, B., van Oosten, A. F., Javed, A. A., Lafaro, K. J., He, J. P., Wolfgang, C. L., & Yu, J. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11081-z · Cited by 20 · see citing works

Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing

Herreros‐Villanueva, M., Bujanda, L., Ruiz-Rebollo, L., Torremocha, R., Ramos, R., Martín, R., & Artigas, M. C. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2021.12.011 · Cited by 20 · see citing works

Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers

Kaczor‐Urbanowicz, K. E., Cheng, J. C., King, J. C., Sedarat, A., Pandol, S. J., Farrell, J. J., Wong, D. T., & Kim, Y. H. (2020) · Pancreas · doi:10.1097/mpa.0000000000001662 · Cited by 20 · see citing works

The Loss of <i>SMAD4/DPC4</i> Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer

Xu, J.-Z., Wang, W.-Q., Zhang, W.-H., Xu, H.-X., Gao, H.-L., Zhang, S.-R., Wu, C.-T., Li, S., Li, H., Xu, J., et al. (2019) · Journal of Cancer · doi:10.7150/jca.30883 · Cited by 19 · see citing works

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel

Malvi, D., Vasuri, F., Maloberti, T., Sanza, V., Leo, A. D., Fornelli, A., Masetti, M., Benini, C., Lombardi, R., Offi, M. F., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12051058 · Cited by 18 · see citing works

Utility of “liquid biopsy” using pancreatic juice for early detection of pancreatic cancer

Okada, T., Iwano, H., Ono, Y., Karasaki, H., Sato, T., Yamada, M., Omori, Y., Sato, H., Hayashi, A., Kawabata, H., et al. (2018) · Endoscopy International Open · doi:10.1055/a-0721-1747 · Cited by 18 · see citing works

Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes

Lu, J., Yu, R., Liu, R., Liang, X., Sun, J. H., Zhang, H., Wu, H., Zhang, Z., Shao, Y. W., Guo, J., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3679 · Cited by 17 · see citing works

Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma

Affolter, K. E., Hellwig, S., Nix, D. A., Bronner, M. P., Thomas, A., Fuertes, C. L., Hamil, C. L., Garrido‐Laguna, I., Scaife, C. L., Mulvihill, S. J., et al. (2021) · Neoplasia · doi:10.1016/j.neo.2021.06.005 · Cited by 16 · see citing works

Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review

Chen, Q., Wang, W.-J., Jia, Y.-X., Yuan, H., Wu, P., Ge, W., Meng, L., Huang, X., Shen, P., Yang, T., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00602-8 · Cited by 16 · see citing works

Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma

Fukuda, J., Kosuge, S., Satoh, Y., Sekiya, S., Yamamura, R., Ooshio, T., Hirata, T., Sato, R., Hatanaka, K. C., Mitsuhashi, T., et al. (2024) · Cancer Science · doi:10.1111/cas.16100 · Cited by 12 · see citing works

Identification and analysis of pancreatic intraepithelial neoplasia: opportunities and challenges

Pian, L.-L., Song, M.-H., Wang, T., Qi, L., Peng, T.-L., & Xie, K.-P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1401829 · Cited by 14 · see citing works

Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients

Kim, M., Kim, M., Kim, S. J., An, S., Park, H., Park, H., Lee, J. H., Song, K.-B., Hwang, D. W., Chang, S., et al. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0416-8 · Cited by 13 · see citing works

Genetics of pancreatic cancer and implications for therapy

Bhosale, P., Cox, V. L., Faria, S. C., Javadi, S., Viswanathan, C., Koay, E. J., & Tamm, E. P. (2017) · Abdominal Radiology · doi:10.1007/s00261-017-1394-y · Cited by 12 · see citing works

Analysis of somatic mutations identifies signs of selection during in vitro aging of primary dermal fibroblasts

Narisu, N., Rothwell, R., Vrtačnik, P., Rodríguez, S., Didion, J. P., Zöllner, S. K., Erdos, M. R., Collins, F. S., & Eriksson, M. (2019) · Aging Cell · doi:10.1111/acel.13010 · Cited by 11 · see citing works

An immune-related gene prognostic risk index for pancreatic adenocarcinoma

Su, Y., Qi, R., Li, L., Wang, X., Li, S., Zhao, X., Hou, R., Ma, W., Liu, D., Zheng, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945878 · Cited by 11 · see citing works

Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG)

Zarkavelis, G., Kotoula, V., Kolliou, G.-A., Papadopoulou, K., Tikas, I. S., Karavasilis, V., Samantas, E., Dervenis, C., Efstratiou, I., Nicolaou, I., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000525 · Cited by 11 · see citing works

Pancreatic ductal adenocarcinoma with a predominant large duct pattern has better recurrence-free survival than conventional pancreatic ductal adenocarcinoma: a comprehensive histopathological, immunohistochemical, and mutational study

Kim, S. J., Choi, S. J., Yang, J., Kim, D., Kim, D. W., Byun, J. H., & Hong, S. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.05.018 · Cited by 9 · see citing works

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma

Taghizadeh, H., Müllauer, L., Mader, R. M., Schindl, M., & Prager, G. W. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920938611 · Cited by 10 · see citing works

Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9

Ono, M., Ono, Y., Nakamura, T., Tsuchikawa, T., Kuraya, T., Kuwabara, S., Nakanishi, Y., Asano, T., Matsui, A., Tanaka, K., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11630-0 · Cited by 10 · see citing works

Exploring the Common Mutational Landscape in Cutaneous Melanoma and Pancreatic Cancer

Broseghini, E., Venturi, F., Veronesi, G., Scotti, B., Migliori, M., Marini, D., Ricci, C., Casadei, R., Ferracin, M., & Dika, E. (2024) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13210 · Cited by 9 · see citing works

Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment

Iwasaki, E., Fukuhara, S., Horibe, M., Kawasaki, S., Seino, T., Takimoto, Y., Tamagawa, H., Machida, Y., Kayashima, A., Noda, M., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11030469 · Cited by 9 · see citing works

The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients

Guo, S., Shi, X., Gao, S., Hou, Q., Jiang, L., Li, B., Shen, J., Wang, H., Shen, S., Zhang, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.717989 · Cited by 9 · see citing works

Decoding pancreatic cancer: key risk factors across genetics and lifestyle

Sharma, R., Ghosh, R., Kumar, S., Komal, K., & Kumar, M. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2464563 · Cited by 9 · see citing works

Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX

Kim, M. K., Cho, I. R., Kim, Y., Choi, J. H., Jung, K., Kim, J., Kim, S., Yun, H., Yoon, J., Oh, D. Y., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241290482 · Cited by 8 · see citing works

The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Survival

Campbell, B. A., Solinas, D., Blackford, A. L., Molin, M. D., Purchla, J., McPhaul, T. J., Chidambaram, S., Cameron, J. L., Lin, M., Hruban, R. H., et al. (2025) · Annals of Surgery · doi:10.1097/sla.0000000000006794 · Cited by 8 · see citing works

Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer

Lee, H. S., Kim, E., Lee, J., Park, S. J., Hwang, H. K., Park, C. H., Jo, S.-Y., Kang, C. M., Hong, S., Kang, H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103218 · Cited by 8 · see citing works

Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Cancer

Dong, J., Liu, J., Zhang, B., Liang, C., Hua, J., Meng, Q., Wei, M., Wang, W., Yu, X., & Xu, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043270 · Cited by 7 · see citing works

Ancillary Techniques in Cytologic Specimens Obtained from Solid Lesions of the Pancreas: A Review

Heymann, J. J., & Siddiqui, M. T. (2019) · Acta Cytologica · doi:10.1159/000497153 · Cited by 7 · see citing works

Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines

Ma, Y., Sender, S., Sekora, A., Kong, W., Bauer, P., Ameziane, N., Krake, S., Radefeldt, M., Al‐Ali, R., Weiß, F. U., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084409 · Cited by 6 · see citing works

Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line

Yanagihara, K., Kubo, T., Mihara, K., Kuwata, T., Ochiai, A., Seyama, T., & Yokozaki, H. (2019) · Pancreas · doi:10.1097/mpa.0000000000001253 · Cited by 6 · see citing works

The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer

Maloney, S., Clarke, S. J., Sahni, S., Hudson, A. L., Colvin, E. K., Mittal, A., Samra, J. S., & Pavlakis, N. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05149-4 · Cited by 5 · see citing works

Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature

Qiu, L., Liu, C., & Li, H. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001546 · Cited by 5 · see citing works

Cancer: Towards a general theory of the target

Vincent, M. D. (2017) · BioEssays · doi:10.1002/bies.201700059 · Cited by 5 · see citing works

Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma

Wen, C., Deng, X., Ren, D., Song, X., Chen, H., Wang, J., Jin, J., Cheng, D., Xu, Z., Zhang, J., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3425 · Cited by 5 · see citing works

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma

Al‐Sukhun, S., & Khalidi, K. (2023) · ecancermedicalscience · doi:10.3332/ecancer.2023.1535 · Cited by 4 · see citing works

SMAD4 loss predicts worse overall and distant metastasis‐free survival in patients with resected pancreatic adenocarcinoma

Anstadt, E. J., Carmona, R., Berlin, E. E., Yegya‐Raman, N., Venigalla, S., Reddy, V. K., Williams, G. R., Leibensperger, M. R., Wojcieszynski, A. P., Baumann, B. C., et al. (2023) · Cancer · doi:10.1002/cncr.35058 · Cited by 3 · see citing works

Clinical utility of comprehensive genomic profiling for advanced pancreatic cancer: insights from real-world data analysis

So, E., Hayashi, H., Shimozaki, K., Horie, S., Kishimoto, S., Chida, A., Saito, Y., Tsugaru, K., Hirata, K., Tanishima, S., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02713-5 · Cited by 2 · see citing works

Liquid biopsy of pancreatic tumors: Challenges for early detection and surveillance based on the molecular landscape during early carcinogenesis

Okada, T., Mizukami, Y., Hayashi, A., Kawabata, H., Sato, H., Kawamoto, T., Goto, T., Taniue, K., Ono, Y., Karasaki, H., et al. (2020) · Suizo · doi:10.2958/suizo.35.302 · Cited by 2 · see citing works

Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: A retrospective cohort study

Zhan, Q., Zhang, L., Wen, C., Yang, Y., Jin, Y., Ren, D., Zhang, Z., Zou, S., Li, F., Sun, H., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000264 · Cited by 3 · see citing works

No Correlation between KRAS Status and Advanced Pancreatic Adenocarcinoma Survival

Ogata, M., Satake, H., Ogata, T., Imai, Y., Hatachi, Y., & Yasui, H. (2017) · Cancer and Clinical Oncology · doi:10.5539/cco.v6n2p45 · Cited by 1 · see citing works

Clinical sequencing of pancreatic cancer in clinical practice

Hayashi, H. (2018) · Suizo · doi:10.2958/suizo.33.915 · Cited by 1 · see citing works

Ancillary Studies in the Cytologic Diagnosis of Pancreatico-biliary Lesions

Heymann, J. J. (2019) · Essentials in cytopathology series · doi:10.1007/978-3-030-22433-2_12

Cancer genomic profiling

Hayashi, H., & Nishihara, H. (2020) · Suizo · doi:10.2958/suizo.35.313

Study on the Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus Using Integrated Bioinformatics MethodPreprint

Liang, J., Zhang, X., & Zhao, W. (2020) · Research Square · doi:10.21203/rs.3.rs-134050/v1

Precision Medicine for Pancreatic Cancer and Cholangiocarcinoma

Morizane, C. (2021) · Springer eBooks · doi:10.1007/978-981-16-2870-2_14

Pathogenesis, Epidemiology, and Prognosis of Pancreatic Adenocarcinomas

Kim, K. K., Gaddam, S., & Liu, Q. Y. (2021) · Hepato-Pancreato-Biliary Malignancies · doi:10.1007/978-3-030-37482-2_28-1

Clinical utility of genome sequencing using liquid biopsy assay in the treatment of pancreatic cancer

Hayashi, H. (2022) · Suizo · doi:10.2958/suizo.37.14

ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma

Ono, M., Nakamura, T., Mizukami, Y., & Hirano, S. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11735-6

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer: Erratum

(2017) · Pancreas · doi:10.1097/mpa.0000000000000882

KRAS, CDKN2A, TP53, And SMAD4 Alterations in Relation to Postoperative Survival and Recurrence Patterns Among Patients with Pancreatic CancerPreprint

Masugi, Y., Takamatsu, M., Tanaka, M. H., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4197932

Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing

Herreros‐Villanueva, M., Bujanda, L., Ruiz-Rebollo, L., Torremocha, R., Ramos, R., Martín, R., & Artigas, M. C. (2022) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.10.001

Pathogenesis, Epidemiology, and Prognosis of Pancreatic Adenocarcinomas

Kim, K. K., Gaddam, S., & Liu, Q. Y. (2022) · Springer eBooks · doi:10.1007/978-3-030-41683-6_28

Expressional correlations between SERPINA6 and pancreatic ductal adenocarcinoma-linked genes

Selver, M., & Tibbetts, L. (2021) · Journal of Emerging Investigators · doi:10.59720/21-050

Genetics and biology of pancreatic ductal adenocarcinoma

Jai, M., & Mozdziak, P. E. (2024) · Medical Journal of Cell Biology · doi:10.2478/acb-2024-0006

Construction of an efferocytosis related signature to predict the prognosis of pancreatic ductal adenocarcinoma

Li, J., Du, Z., Liu, X., Pan, T., Zheng, Y., & He, Y. (2026) · Discover Oncology · doi:10.1007/s12672-026-05088-9

Predicting and assessing the response of borderline resectable pancreatic cancer to neoadjuvant chemotherapy: Methodological approaches

Yang, X., He, K., Wang, X., Jiang, Q., Wang, W., & Wu, D. (2026) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000260

Gene Mutation Profile of Pancreatic Cancer Obtained Using Targeted Deep Sequencing and Its Association with Prognosis

Hayashi, H., Kohno, T., Hiraoka, N., Sakamoto, Y., Kondo, S., Morizane, C., Saito, M., Shimada, K., Ichikawa, H., Komatsu, Y., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu334.74 · Cited by 1 · see citing works

Gene Mutation Profile of Pancreatic Cancer in Japanese Patients and Its Association with Prognosis

Hayashi, H., Ueno, H., Sakamoto, Y., Kondo, S., Morizane, C., Shimada, K., Ichikawa, H., Hiraoka, N., Kohno, T., & Okusaka, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu435.79

Clinical Effect of Driver Mutations of <i>KRAS, CDKN2A/P16, TP53</i> , and <i>SMAD4</i> in Pancreatic Cancer: A Meta-Analysis

Gu, Y., Ji, Y., Jiang, H., & Qiu, G. (2020) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2020.0078 · Cited by 28 · see citing works

Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes

Lu, J., Yu, R., Liu, R., Liang, X., Sun, J. H., Zhang, H., Wu, H., Zhang, Z., Shao, Y. W., Guo, J., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3679 · Cited by 17 · see citing works

Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome

Shoucair, S., Habib, J. R., Pu, N., Kinny‐Köster, B., van Oosten, A. F., Javed, A. A., Lafaro, K. J., He, J. P., Wolfgang, C. L., & Yu, J. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11081-z · Cited by 20 · see citing works